Researchers at the Queensland University of Technology found that the extract of San Francisco
plant (Codiaeum variegatum) found in Australia, can kill the zika virus. This extract can arrest the
virus and stop it from replicating without causing any damage to the host cells.
Continuous increase in human clinical trials and rise in number of zika cases will drive the
growth of Zika vaccines market
As of March 2016, 67 companies and research institutions were working on various kinds of R&D
projects and clinical trials aided to develop effective vaccines against zika virus. The FDA approved
the first human clinical trial for GLS–5700 in June 2016, a zika vaccine being developed by Inovio
Pharmaceuticals. Further in 2017, a grant was approved for phase 2 clinical trials for a DNA
vaccine conducted by NIAID’s Vaccine Research Center (VRC).
Increasing awareness among the population would aid in controlling the incidence rate of zika
infection. The WHO implemented a global framework for creating public awareness through its
Zika Strategic Response Framework and Joint Plan in February 2016. This plan outlines all the
points to be taken care of at the time of infections. In June 2016, WHO Regional Office for Europe
developed a training curriculum to increase awareness by the publication of Zika Risk Assessment
for European Region.
For More Information @ https://www.coherentmarketinsights.com/ongoing-insight/zika-
vaccines-market-413
High investment costs required for R&D and the development of effective zika virus vaccines
serves as a restraining factor for the global zika vaccines market.
While major of the Zika virus cases occur in tropical regions such as Brazil, Paraguay, Venezuela,
Colombia and Suriname, there are higher chances of mosquito infections in tropical areas of the
U.S. like Texas and Florida. According to Pan American Health Organization, around 1,246
suspected and confirmed cases were reported between epidemiological week (EW) 10 and EW 14
of 2016 in the sub region which involves Brazil, Argentina, Peru and Ecuador.
Competitive Landscape
Some key players operating in the zika vaccines market are Cerus Corporation, Biken Inc,
GlaxoSmithKline plc, Bharat Biotech International Pvt. Ltd, GeneOne Life Science, Inovio
Pharmaceuticals, Immunovaccine Inc., NewLink Genetics Corp. and Sanofi S.A. The companies
launched various R&D measures and clinical trials to attain immunogenicity against zika virus. In
February 2016, Sanofi S.A launched a vaccine research and development project, with the
introduction of Dengvaxia (Dengue vaccine) that will aid the company understand the Zika virus
and develop an effective vaccine against it. Likewise, Inovio Pharmaceuticals initiated a clinical
study of zika vaccine (GLS-5700) in Puerto Rico in August 2016. This trial may provide a potential
push to Inovio’s vaccine if positive results are reported as there was a rapid progression of zika
outbreak in Puerto Rico at that time. This could benefit the trial in assessing true efficacy and safety
of the vaccine. Rapid progression in clinical trials and approval would augment the zika vaccines
market growth.
Zika Vaccines Market Taxonomy:
There are different types of vaccines that provide protection against Zika virus:
•DNA-based vaccines
•Inactivated vaccines
•Live-attenuated vaccines